We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

PURCHASING ACTEMRA® (tocilizumab)

Current as of March 2022
Please note: We are reviewing this page weekly and information is updated as relevant or necessary.

If you are a patient seeking information on Actemra IV or SC please contact our Patient Resource Center at (877-436-3683).

Thank you for your continued patience as Genentech works to stabilize ACTEMRA® (tocilizumab) supply. Genentech is pleased to announce the following first step toward consistent, uninterrupted patient access.

  • Due to increased replenishments of Actemra IV Genentech is removing allocations to distributors for IV 400mg, 200mg, and 80mg.
  • Each distributor may have a different approach to managing their inventory to their respective customers.
  • Please note that the most up-to-date information on product availability across the Actemra IV and/or SC formulations will be available through your authorized distributors. For Actemra IV availability information, customers may refer to the distributors’ online ordering portal or customer service line.

Update to Return Goods Policy for Actemra IV:

Genentech will not accept returns for Actemra IV purchased on or after August 30, 2021 until further notice. The updated policy for expired returns is now available.

To receive email alerts as this page is updated, please sign up below.

To receive email alerts as this page is updated, please sign up below.

Protecting your patients from illegitimate medicines

ACTEMRA is available only through authorized distributors that have made a commitment to product integrity.

Be cautious of new or unfamiliar distributors that offer ACTEMRA at substantially lower prices that may be "too good to be true"; the product being offered may be illegitimate.

If you suspect that you have received an illegitimate medicine, contact Genentech's Product Complaint Hotline at 1-800-334-0290, and file a report with the FDA’s Office of Criminal Investigations (OCI): call 1-800-551-3989 or visit www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm